The estimated Net Worth of Thomas A Mitro is at least $6.48 Million dollars as of 27 August 2018. Mr. Mitro owns over 190,000 units of Aerie Pharmaceuticals Inc stock worth over $3,682,555 and over the last 11 years he sold AERI stock worth over $0. In addition, he makes $2,792,980 as President and Chief Operating Officer at Aerie Pharmaceuticals Inc.
Thomas has made over 2 trades of the Aerie Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 190,000 units of AERI stock worth $598,500 on 27 August 2018.
The largest trade he's ever made was exercising 190,000 units of Aerie Pharmaceuticals Inc stock on 27 August 2018 worth over $598,500. On average, Thomas trades about 8,864 units every 80 days since 2013. As of 27 August 2018 he still owns at least 241,479 units of Aerie Pharmaceuticals Inc stock.
You can see the complete history of Mr. Mitro stock trades at the bottom of the page.
Thomas A. Mitro serves as President, Chief Operating Officer of the Company. From November 2012 to August 2013, Mr. Mitro served as Vice President, Sales and Marketing at Omeros Corporation, a clinical-stage biopharmaceutical company. Prior to this, Mr. Mitro was Vice President, Sales and Marketing at ISTA Pharmaceuticals from July 2002 to July 2012, where he was instrumental in building ISTA’s commercial operations and launching several eye-care products, including Bromday (bromfenac ophthalmic solution) 0.09% and Bepreve (bepotastine besilate ophthalmic solution) 1.5%. Previously, Mr. Mitro held various positions at Allergan, Inc., including Vice President, Skin Care; Vice President, Business Development; and Vice President, e-Business. Mr. Mitro received his B.S. from Miami University.
As the President and Chief Operating Officer of Aerie Pharmaceuticals Inc, the total compensation of Thomas Mitro at Aerie Pharmaceuticals Inc is $2,792,980. There are 1 executives at Aerie Pharmaceuticals Inc getting paid more, with Vicente Anido having the highest compensation of $5,529,670.
Thomas Mitro is 62, he's been the President and Chief Operating Officer of Aerie Pharmaceuticals Inc since 2013. There are 9 older and 10 younger executives at Aerie Pharmaceuticals Inc. The oldest executive at Aerie Pharmaceuticals Inc is Gerald Cagle, 75, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM, NC, 27703.
Over the last 11 years, insiders at Aerie Pharmaceuticals Inc have traded over $194,685,628 worth of Aerie Pharmaceuticals Inc stock and bought 2,240,245 units worth $39,233,665 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Anand Mehra, and Capital Management Ii, Llc .... On average, Aerie Pharmaceuticals Inc executives and independent directors trade stock every 45 days with the average trade being worth of $2,718,618. The most recent stock trade was executed by Casey C. Kopczynski on 15 February 2021, trading 60,651 units of AERI stock currently worth $12,130.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Aerie Pharmaceuticals Inc executives and other stock owners filed with the SEC include: